Tego Science테고사이언스

Tego Science remains loss-making on a trailing basis, with revenue shrinking and the share price down sharply over the past year.

Tego Science is a Korean cell therapy and tissue-model company with trailing twelve-month revenue of about ₩6.2B and an operating loss of about ₩6.1B through H1 2026. The shares trade near ₩7,260, roughly 60% below a year ago and well below their 52-week high of ₩18,770, with a market value of about ₩58.9B. The data shows no current earnings-based valuation, and the company pays no dividend.

What stands out

• Revenue fell 12.1% in 2025 to about ₩5.9B, and trailing revenue of ₩6.2B has not reversed the decline seen since 2024.
• Operating margin was -98.6% on a trailing basis, and net loss was about ₩12.9B, which is larger than the operating loss.
• Cash of about ₩5.7B exceeds borrowings of about ₩2.4B, but free cash flow was negative about ₩6.0B over the trailing period.
• The 2024 profit of about ₩3.3B came after several years of losses and does not appear to reflect ongoing operations, based on the operating figures.
• Foreign ownership fell from 1.9% to 1.3% over 60 days, while the 20-day flows show foreign and institutional net selling against net retail buying.

What to watch

• Next quarterly and annual filings, to see whether revenue stabilises and losses narrow from the H1 2026 levels.
• Cash runway, given negative free cash flow and the company's borrowings; the data does not state a funding plan.
• Shareholder and insider filings from September 2026 and the May 2026 share acquisition, whose purpose is not described in the data.